Human Genome Epidemiology Literature Finder
|
Records 1 - 5 (of 5 Records) |
| Query Trace: Prostatic Hyperplasia and CYP2D6[original query] |
|---|
| Effects of CYP2D6 and CYP3A5 genetic polymorphisms on steady-state pharmacokinetics and hemodynamic effects of tamsulosin in humans. European journal of clinical pharmacology 2018 Jun . Kim Kyoung-Ah, Park In-Bae, Park Ji-You |
| Physiologically based pharmacokinetic (PBPK) modelling of tamsulosin related to CYP2D6*10 allele. Archives of pharmacal research 2021 11 44 (11): 1037-1049. Cho Chang-Keun, Kang Pureum, Park Hye-Jung, Lee Yun Jeong, Bae Jung-Woo, Jang Choon-Gon, Lee Seok-Yo |
| Effects of Cytochrome P450 and Transporter Polymorphisms on the Bioavailability and Safety of Dutasteride and Tamsulosin. Frontiers in pharmacology 2021 10 12 718281. Villapalos-García Gonzalo, Zubiaur Pablo, Navares-Gómez Marcos, Saiz-Rodríguez Miriam, Mejía-Abril Gina, Martín-Vílchez Samuel, Román Manuel, Ochoa Dolores, Abad-Santos Francis |
| Effects of CYP2D6 allelic variants on therapy with tamsulosin in patients with benign prostatic hyperplasia. Drug metabolism and personalized therapy 2023 9 . Skokhrukh P Abdullaev, Maksim N Shatokhin, Svetlana N Tuchkova, Sherzod P Abdullaev, Oleg V Teodorovich, Oleg B Loran, Dmitry A Sych |
| [Study of allelic variants of the CYP2D6 and CYP3A genes on the effectiveness and safety of tamsulosin therapy in patients with BPH: results of a pilot study]. Urologiia (Moscow, Russia : 1999) 2023 12 (6): 5-13. P Abdullaev Sh, N Shatokhin M, N Tuchkova S, P Abdullaev Sh, V Teodorovich O, B Loran O, A Sychev |
- Page last reviewed:Feb 1, 2024
- Content source: